Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 4;55(9):1531–1541. doi: 10.1038/s41588-023-01480-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 8 — a, Point mutations and cytogenetic abnormalities identified in a cohort of 6 CP TP53-MPN patients with no evidence of clinical transformation after 4.43 years [2.62-5.94] median follow-up. The number of patients in which each gene is mutated is shown on the barplot on the right and patients processed for TARGET-seq analysis are indicated below the heatmap. b, Summary of CNA events in chr17 and TP53 gene in the 2 CP TP53-MPN patients with detectable CNAs. The top panel shows a whole chromosome view and the bottom one, the gene-level view and RefSeq track. Points indicate the location of each point mutation and solid horizontal lines indicate CNA status. c-e, Comparison of variant allele frequency (c), number of TP53 mutations (d) and pathogenic scores (e) of TP53 variants identified in CP-TP53-MPN (n = 6) and TP53-sAML patients (n = 33). Mean ± s.e.m. is shown; “p” indicates two-tailed Mann^-Whitney test p-value. f, Location and mutation type stratified by patient group (chronic/acute phase) as compared to previously published CHIP and AML patient cohorts.